Morningstar has a “hold" recommendation on Acrux Ltd. It said that following the recent Drug Safety Communication, or DSC, issued by the US Food and Drug Administration, or FDA, analysts met with Acrux management and undertook a review of growth assumptions underpinning the transdermal testosterone therapy market opportunity.
“Following the review, our fair value estimate for Acrux decreases from $4.20 to $2.50," Morningstar said.
Loading...
Elise Shaw writes on Markets specialising in Equity Markets, Commodities, Mining. Based in our Sydney newsroom, Elise has over 25 years experience as a finance and markets journalist and editor. Connect with Elise on Twitter.
